Single-cell profiling identifies pre-existing CD19-negative subclones in a B-ALL patient with CD19-negative relapse after CAR-T therapy

Chimeric antigen receptor T cell (CAR-T) targeting the CD19 antigen represents an innovative therapeutic approach to improve the outcome of relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). Yet, despite a high initial remission rate, CAR-T therapy ultimately fails for some patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Rabilloud, Tracy, Potier, Delphine, Pankaew, Saran, Nozais, Mathis, Loosveld, Marie, Payet-Bornet, Dominique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7870924/
https://www.ncbi.nlm.nih.gov/pubmed/33558546
http://dx.doi.org/10.1038/s41467-021-21168-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7870924/
https://www.ncbi.nlm.nih.gov/pubmed/33558546
http://dx.doi.org/10.1038/s41467-021-21168-6

Ejemplares similares